慢性閉塞性肺疾患（COPD）および喘息治療薬市場規模、成長と動向分析レポート 2025-2030年

COPDおよび喘息治療薬市場は、Bluetooth接続機能を備えたスマート吸入器やAIベースの呼吸モニタリング・プラットフォームといった薬剤投与デバイスの技術進歩によっても推進されています。これらのデバイスは、治療遵守の向上と遠隔での患者管理を可能にします。Propeller HealthやTevaなどの企業は、薬剤の使用状況を追跡し、データを臨床医にリアルタイムで送信するFDA承認のスマート吸入器を発売しています。

COPD & Asthma Therapeutics Market Trends

The global COPD and asthma therapeutics market size was valued at USD 92.30 billion in 2024 and is expected to grow at a CAGR of 9.18% from 2025 to 2030. The increasing prevalence of chronic respiratory conditions, exacerbated by rising pollution levels, tobacco consumption, and aging populations, is significantly boosting demand for bronchodilators, corticosteroids, and combination therapies.

世界の慢性閉塞性肺疾患（COPD）および喘息治療薬市場規模は2024年に923億米ドルと評価され、2025年から2030年にかけて9.18%のCAGRで成長すると予想されています。大気汚染レベルの上昇、タバコの消費、人口の高齢化によって慢性呼吸器疾患の罹患率が増加しており、気管支拡張薬、コルチコステロイド、併用療法の需要が大幅に高まっています。

For instance, according to the Global Initiative for Asthma (GINA), asthma affected over 262 million people globally in 2022, while the WHO reported that COPD was the third leading cause of death worldwide. In addition, a growing aging population coupled with increasing automotive and industrial exhaust gases remains the key driver for the global COPD and asthma therapeutics industry. Degrading air quality near industrial areas has led to an increased incidence of asthma. According to the European Environment Agency, air pollutant levels in 2021 significantly exceeded the levels specified by the World Health Organization’s (WHO) air quality guidelines. Achieving these recommended levels could have prevented a significant number of deaths across EU Member States (EU-27), including 253,000 deaths linked to exposure to fine particulate matter (PM2.5) and 52,000 deaths caused by nitrogen dioxide (NO2) exposure. In addition, reducing short-term exposure to ozone (O3) could have reduced 22,000 attributable deaths.

例えば、世界喘息イニシアチブ（GINA）によると、2022年には世界で2億6,200万人以上が喘息に罹患し、WHOはCOPDが世界で3番目に多い死因であると報告しました。さらに、高齢化の進展と自動車および産業からの排気ガスの増加が相まって、世界のCOPDおよび喘息治療産業にとって依然として重要な原動力となっています。工業地帯付近の大気質の悪化は、喘息の発生率増加につながっています。欧州環境機関によると、2021年の大気汚染レベルは、世界保健機関（WHO）の大気質ガイドラインで指定されたレベルを大幅に上回りました。これらの推奨レベルを達成していれば、EU​​加盟国（EU-27）全体で、微小粒子状物質（PM2.5）への曝露に関連する253,000人の死亡と二酸化窒素（NO2）への曝露による52,000人の死亡を含む、かなりの数の死亡を防ぐことができた可能性があります。さらに、オゾン（O3）への短期的な曝露を減らすことで、22,000人の死亡者を減らすことができた可能性があります。

The COPD and asthma therapeutics market is also propelled by technological advancements in drug delivery devices, such as smart inhalers with Bluetooth connectivity and AI-based respiratory monitoring platforms, which enhance treatment adherence and enable remote patient management. Companies like Propeller Health and Teva have introduced FDA-approved smart inhalers that track medication usage and transmit data to clinicians in real time.

Moreover, the growing penetration of mobile health apps and telepulmonology solutions is improving access to care, especially in underserved areas. The expansion of online pharmacies and direct-to-consumer digital platforms is also streamlining therapy access, supporting the shift towards home-based disease management. Collectively, these advancements across therapeutic classes, delivery devices, and digital tools are expected to drive sustained growth in the COPD and asthma market through 2030.

Increasing healthcare expenditure, improved access to care in developing regions, and supportive government initiatives aimed at managing chronic respiratory conditions are further enhancing market potential. The rise of universal healthcare programs in countries such as India and China is expanding access to essential inhalers and diagnostics. For instance, China’s Healthy China 2030 initiative focuses on four strategic pillars: equitable access and outcomes in health and healthcare, healthcare systems transformation, technology and innovation, and environmental and climate sustainability. Equity is the foundational goal, guiding efforts to reduce barriers in healthcare systems and improve health outcomes across the country.

The COVID-19 pandemic positively impacted the COPD and asthma therapeutics industry. Initially, disruptions in healthcare access, reduced pulmonary function testing, and delayed diagnoses led to a decline in treatment rates and prescription volumes. However, as the pandemic progressed, heightened awareness of respiratory health and the increased risk of severe COVID-19 outcomes in patients with chronic lung diseases drove greater adherence to maintenance therapies. The shift toward home-based care, telemedicine, and digital health tools, such as smart inhalers and remote monitoring, supported continued treatment and patient engagement. While the market faced short-term setbacks, the pandemic ultimately reinforced the importance of proactive respiratory care, leading to long-term growth opportunities.

COPD And Asthma Therapeutics Market Report Scope

Global COPD And Asthma Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global COPD and asthma therapeutics market report based on drug class, device/product, technology/software, indication, distribution channel, and region:

• Drug Class Outlook (Revenue, USD Million, 2018 – 2030)
• Bronchodilators
• Corticosteroids
• Leukotriene Modifiers
• Anti-IgE and Anti-IL Monoclonal Antibodies
• Combination Therapy
• Others
• Device/Product Outlook (Revenue, USD Million, 2018 – 2030)
• Inhalers

o Dry Powder Inhalers (DPI)

o Metered Dose Inhalers (MDI)

o Soft Mist Inhalers (SMI)

• Nebulizers

o Jet

o Mesh

o Ultrasonic

• Oxygen Therapy Devices
• Technology/Software Outlook (Revenue, USD Million, 2018 – 2030)
• Smart Inhalers with Bluetooth Connectivity
• AI-based Respiratory Monitoring Platforms
• Mobile Apps for Symptom Tracking
• Digital Adherence and Reminder Systems
• Telepulmonology Solutions
• Indication Outlook (Revenue, USD Million, 2018 – 2030)
• Asthma
• COPD
• Distribution Channel Outlook (Revenue, USD Million, 2018 – 2030)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Regional Outlook (Revenue, USD Million, 2018 – 2030)
• North America

o U.S.

o Canada

o Mexico

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o Japan

o India

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Table of Contents

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope

1.2. Segment Definitions

1.2.1. Drug Class

1.2.2. Device/Product

1.2.3. Technology/Software

1.2.4. Indication

1.2.5. Distribution Channel

1.3. Estimates and Forecast Timeline

1.4. Research Methodology

1.5. Information Procurement

1.5.1. Purchased Database

1.5.2. GVR’s Internal Database

1.5.3. Secondary Sources

1.5.4. Primary Research

1.6. Information Analysis

1.6.1. Data Analysis Models

1.7. Market Formulation & Data Visualization

1.8. Model Details

1.8.1. Commodity Flow Analysis

1.9. List of Secondary Sources

1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot

2.2. Segment Snapshot

2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook

3.2. Market Dynamics

3.2.1. Market Driver Analysis

3.2.1.1. Emergence of novel biologics

3.2.1.2. Growing adoption of AI technologies in diagnostics, remote monitoring, and treatment optimization.

3.2.1.3. Advancements in smart inhalers and digital health tools enhancing patient adherence and outcomes.

3.2.1.4. Strong pipeline of innovative drugs and fixed-dose combination therapies.

3.2.2. Market Restraint Analysis

3.2.2.1. Regulatory hurdles and lengthy approval timelines for novel therapeutics.

3.2.2.2. High cost of biologics and advanced therapies

3.2.3. Industry Opportunity Analysis

3.2.4. Industry Challenge Analysis

3.2.5. Case Studies

3.3. Business Environment Analysis

3.3.1. Porter’s Five Forces Analysis

3.3.1.1. Supplier power

3.3.1.2. Buyer power

3.3.1.3. Substitution threat

3.3.1.4. Threat of new entrants

3.3.1.5. Competitive rivalry

3.3.2. PESTLE Analysis

3.4. COVID-19 Impact Analysis

Chapter 4. COPD and Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis

4.1. Drug Class Segment Dashboard

4.2. Drug Class Market Share Movement Analysis, 2024 & 2030

4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)

4.3.1. Bronchodilators

4.3.1.1. Bronchodilators market, 2018 – 2030 (USD Million)

4.3.2. Corticosteroids

4.3.2.1. Corticosteroids market, 2018 – 2030 (USD Million)

4.3.3. Leukotriene Modifiers

4.3.3.1. Leukotriene Modifiers market, 2018 – 2030 (USD Million)

4.3.4. Anti-IgE and Anti-IL Monoclonal Antibodies

4.3.4.1. Anti-IgE and Anti-IL Monoclonal Antibodies market, 2018 – 2030 (USD Million)

4.3.5. Combination Therapy

4.3.5.1. Combination Therapy market, 2018 – 2030 (USD Million)

4.3.6. Others

4.3.6.1. Others market, 2018 – 2030 (USD Million)

Chapter 5. COPD and Asthma Therapeutics Market: Device/Product Estimates & Trend Analysis

5.1. Device/Product Dashboard

5.2. Device/Product Market Share Movement Analysis, 2024 & 2030

5.3. Market Size & Forecasts and Trend Analysis, by Device/Product, 2018 to 2030 (USD Million)

5.4. Inhalers

5.4.1. Inhalers market, 2018 – 2030 (USD Million)

5.4.1.1. Dry Powder Inhalers

5.4.1.1.1.Dry Powder Inhalers market, 2018 – 2030 (USD Million)

5.4.1.2. Metered Dose Inhalers

5.4.1.2.1.Metered Dose Inhalers market, 2018 – 2030 (USD Million)

5.4.1.3. Soft Mist Inhalers

5.4.1.3.1.Soft Mist Inhalers market, 2018 – 2030 (USD Million)

5.5. Nebulizers

5.5.1. Nebulizers market, 2018 – 2030 (USD Million)

5.5.1.1. Jet nebulizers

5.5.1.1.1. Jet nebulizers market, 2018 – 2030 (USD Million)

5.5.1.2. Mesh nebulizers

5.5.1.2.1. Mesh nebulizers market, 2018 – 2030 (USD Million)

5.5.1.3. Ultrasonic

5.5.1.3.1. Ultrasonic Inhalers market, 2018 – 2030 (USD Million)

5.6. Oxygen Therapy Devices

5.6.1. Oxygen Therapy Devices market, 2018 – 2030 (USD Million)

Chapter 6. COPD and Asthma Therapeutics Market: Technology/Software Estimates & Trend Analysis

6.1. Technology/Software Segment Dashboard

6.2. Technology/Software Market Share Movement Analysis, 2024 & 2030

6.3. Market Size & Forecasts and Trend Analysis, by Technology/Software, 2018 to 2030 (USD Million)

6.4. Smart Inhalers with Bluetooth Connectivity

6.4.1. Smart Inhalers with Bluetooth Connectivity market, 2018 – 2030 (USD Million)

6.5. AI-based Respiratory Monitoring Platforms

6.5.1. AI-based Respiratory Monitoring Platforms market, 2018 – 2030 (USD Million)

6.6. Mobile Apps for Symptom Tracking

6.6.1. Mobile Apps for Symptom Tracking market, 2018 – 2030 (USD Million)

6.7. Digital Adherence and Reminder Systems

6.7.1. Digital Adherence and Reminder Systems market, 2018 – 2030 (USD Million)

6.8. Telepulmonology Solutions

6.8.1. Telepulmonology Solutions market, 2018 – 2030 (USD Million)

Chapter 7. COPD and Asthma Therapeutics Market: Indication Estimates & Trend Analysis

7.1. Indication Segment Dashboard

7.2. Indication Market Share Movement Analysis, 2024 & 2030

7.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)

7.4. Asthma

7.4.1. Asthma market, 2018 – 2030 (USD Million)

7.5. COPD

7.5.1. COPD market, 2018 – 2030 (USD Million)

Chapter 8. COPD and Asthma Therapeutics Market: Distribution Channel Estimates & Trend Analysis

8.1. Distribution Channel Segment Dashboard

8.2. Distribution Channel Market Share Movement Analysis, 2024 & 2030

8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)

8.4. Hospital Pharmacies

8.4.1. Hospital Pharmacies market, 2018 – 2030 (USD Million)

8.5. Retail Pharmacies

8.5.1. Retail Pharmacies market, 2018 – 2030 (USD Million)

8.6. Online Pharmacies

8.6.1. Drug Stores market, 2018 – 2030 (USD Million)

Chapter 9. COPD and Asthma Therapeutics Market: Regional Estimates & Trend Analysis

9.1. Regional Market Dashboard

9.2. Regional Market: Key Takeaways

9.3. North America

9.3.1. North America COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.3.2. U.S.

9.3.2.1. Key country dynamic

9.3.2.2. Regulatory framework

9.3.2.3. Competitive insights

9.3.2.4. U.S. COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.3.3. Canada

9.3.3.1. Key country dynamic

9.3.3.2. Regulatory framework

9.3.3.3. Competitive insights

9.3.3.4. Canada COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.3.4. Mexico

9.3.4.1. Key country dynamic

9.3.4.2. Regulatory framework

9.3.4.3. Competitive insights

9.3.4.4. Mexico COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.4. Europe

9.4.1. Europe COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.4.2. Germany

9.4.2.1. Key country dynamic

9.4.2.2. Regulatory framework

9.4.2.3. Competitive insights

9.4.2.4. Germany COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.4.3. UK

9.4.3.1. Key country dynamic

9.4.3.2. Regulatory framework

9.4.3.3. Competitive insights

9.4.3.4. UK COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.4.4. France

9.4.4.1. Key country dynamic

9.4.4.2. Regulatory framework

9.4.4.3. Competitive insights

9.4.4.4. France COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.4.5. Italy

9.4.5.1. Key country dynamic

9.4.5.2. Regulatory framework

9.4.5.3. Competitive insights

9.4.5.4. Italy COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.4.6. Spain

9.4.6.1. Key country dynamic

9.4.6.2. Regulatory framework

9.4.6.3. Competitive insights

9.4.6.4. Spain COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.4.7. Denmark

9.4.7.1. Key country dynamic

9.4.7.2. Regulatory framework

9.4.7.3. Competitive insights

9.4.7.4. Denmark COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.4.8. Sweden

9.4.8.1. Key country dynamic

9.4.8.2. Regulatory framework

9.4.8.3. Competitive insights

9.4.8.4. Sweden COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.4.9. Norway

9.4.9.1. Key country dynamic

9.4.9.2. Regulatory framework

9.4.9.3. Competitive insights

9.4.9.4. Norway COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.5. Asia Pacific

9.5.1. Asia Pacific COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.5.2. Japan

9.5.2.1. Key country dynamic

9.5.2.2. Regulatory framework

9.5.2.3. Competitive insights

9.5.2.4. Japan COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.5.3. China

9.5.3.1. Key country dynamic

9.5.3.2. Regulatory framework

9.5.3.3. Competitive insights

9.5.3.4. China COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.5.4. India

9.5.4.1. Key country dynamic

9.5.4.2. Regulatory framework

9.5.4.3. Competitive insights

9.5.4.4. India COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.5.5. South Korea

9.5.5.1. Key country dynamic

9.5.5.2. Regulatory framework

9.5.5.3. Competitive insights

9.5.5.4. South Korea COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.5.6. Australia

9.5.6.1. Key country dynamic

9.5.6.2. Regulatory framework

9.5.6.3. Competitive insights

9.5.6.4. Australia COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.5.7. Thailand

9.5.7.1. Key country dynamic

9.5.7.2. Regulatory framework

9.5.7.3. Competitive insights

9.5.7.4. Thailand COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.6. Latin America

9.6.1. Latin America COPD and Asthma Therapeutics Market Estimates and Forecasts, 2018 – 2030 (USD Million)

9.6.2. Brazil

9.6.2.1. Key country dynamic

9.6.2.2. Regulatory framework

9.6.2.3. Competitive insights

9.6.2.4. Brazil COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.6.3. Argentina

9.6.3.1. Key country dynamic

9.6.3.2. Regulatory framework

9.6.3.3. Competitive insights

9.6.3.4. Argentina COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.7. MEA

9.7.1. MEA COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.7.2. South Africa

9.7.2.1. Key country dynamic

9.7.2.2. Regulatory framework

9.7.2.3. Competitive insights

9.7.2.4. South Africa COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.7.3. Saudi Arabia

9.7.3.1. Key country dynamic

9.7.3.2. Regulatory framework

9.7.3.3. Competitive insights

9.7.3.4. Saudi Arabia COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.7.4. UAE

9.7.4.1. Key country dynamic

9.7.4.2. Regulatory framework

9.7.4.3. Competitive insights

9.7.4.4. UAE COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

9.7.5. Kuwait

9.7.5.1. Key country dynamic

9.7.5.2. Regulatory framework

9.7.5.3. Competitive insights

9.7.5.4. Kuwait COPD and asthma therapeutics market estimates and forecasts, 2018 – 2030 (USD Million)

Chapter 10. Competitive Landscape

10.1. Participant Overview

10.2. Company Market Position Analysis

10.3. Company Categorization

10.4. Strategy Mapping

10.5. Company Profiles/Listing

10.5.1. Teva Pharmaceutical Industries Ltd.

10.5.1.1. Overview

10.5.1.2. Financial performance

10.5.1.3. Product benchmarking

10.5.1.4. Strategic initiatives

10.5.2. GSK plc

10.5.2.1. Overview

10.5.2.2. Financial performance

10.5.2.3. Product benchmarking

10.5.2.4. Strategic initiatives

10.5.3. Merck & Co., Inc.

10.5.3.1. Overview

10.5.3.2. Financial performance

10.5.3.3. Product benchmarking

10.5.3.4. Strategic initiatives

10.5.4. F. Hoffmann-La Roche Ltd

10.5.4.1. Overview

10.5.4.2. Financial performance

10.5.4.3. Product benchmarking

10.5.4.4. Strategic initiatives

10.5.5. AstraZeneca

10.5.5.1. Overview

10.5.5.2. Financial performance

10.5.5.3. Product benchmarking

10.5.5.4. Strategic initiatives

10.5.6. Boehringer Ingelheim International GmbH

10.5.6.1. Overview

10.5.6.2. Financial performance

10.5.6.3. Product benchmarking

10.5.6.4. Strategic initiatives

10.5.7. Sanofi

10.5.7.1. Overview

10.5.7.2. Financial performance

10.5.7.3. Product benchmarking

10.5.7.4. Strategic initiatives

10.5.8. Koninklijke Philips N.V.

10.5.8.1. Overview

10.5.8.2. Financial performance

10.5.8.3. Product benchmarking

10.5.8.4. Strategic initiatives

10.5.9. BD

10.5.9.1. Overview

10.5.9.2. Financial performance

10.5.9.3. Product benchmarking

10.5.10. Covis Pharma

10.5.10.1. Overview

10.5.10.2. Financial performance

10.5.10.3. Product benchmarking

10.5.11. Findair Sp. z o. o.

10.5.11.1. Overview

10.5.11.2. Financial performance

10.5.11.3. Product benchmarking

10.5.12. Novartis AG

10.5.12.1. Overview

10.5.12.2. Financial performance

10.5.12.3. Product benchmarking

10.5.13. F. Hoffmann-La Roche Ltd

10.5.13.1. Overview

10.5.13.2. Financial performance

10.5.13.3. Product benchmarking

10.5.14. Cipla Ltd.

10.5.14.1. Overview

10.5.14.2. Financial performance

10.5.14.3. Product benchmarking

10.5.15. Chiesi Air

10.5.15.1. Overview

10.5.15.2. Financial performance

10.5.15.3. Product benchmarking

List of Tables

Table 1. List of secondary sources

Table 2. List of abbreviations

Table 3. North America COPD and asthma therapeutics market, by country, 2018 – 2030 (USD Million)

Table 4. North America COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 5. North America COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 6. North America COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 7. North America COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 8. North America COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 9. U.S. COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 10. U.S. COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 11. U.S. COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 12. U.S. COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 13. U.S. COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 14. Canada COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 15. Canada COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 16. Canada COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 17. Canada COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 18. Canada COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 19. Mexico COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 20. Mexico COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 21. Mexico COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 22. Mexico COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 23. Mexico COPD and asthma therapeutics market, by distribution channel scope, 2018-

Table 24. Europe COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 25. Europe COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 26. Europe COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 27. Europe COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 28. Europe COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 29. UK COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 30. UK COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 31. UK COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 32. UK COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 33. UK COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 34. Germany COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 35. Germany COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 36. Germany COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 37. Germany COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 38. Germany COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 39. France COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 40. France COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 41. France COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 42. France COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 43. France COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 44. Italy COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 45. Italy COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 46. Italy COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 47. Italy COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 48. Italy COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 49. Spain COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 50. Spain COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 51. Spain COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 52. Spain COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 53. Spain COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 54. Norway COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 55. Norway COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 56. Norway COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 57. Norway COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 58. Norway COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 59. Sweden COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 60. Sweden COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 61. Sweden COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 62. Sweden COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 63. Sweden COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 64. Denmark COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 65. Denmark COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 66. Denmark COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 67. Denmark COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 68. Denmark COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 69. Asia Pacific COPD and asthma therapeutics market, by country, 2018 – 2030 (USD Million)

Table 70. Asia Pacific COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 71. Asia Pacific COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 72. Asia Pacific COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 73. Asia Pacific COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 74. Asia Pacific COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 75. Japan COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 76. Japan COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 77. Japan COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 78. Japan COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 79. Japan COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 80. China COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 81. China COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 82. China COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 83. China COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 84. China COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 85. India COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 86. India COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 87. India COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 88. India COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 89. India COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 90. Australia COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 91. Australia COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 92. Australia COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 93. Australia COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 94. Australia COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 95. South Korea COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 96. South Korea COPD and asthma therapeutics market, by application, 2018 – 2030 (USD Million)

Table 97. South Korea COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 98. South Korea COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 99. South Korea COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 100. Thailand COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 101. Thailand COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 102. Thailand COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 103. Thailand COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 104. Thailand COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 105. Latin America COPD and asthma therapeutics market, by country, 2018 – 2030 (USD Million)

Table 106. Latin America COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 107. Latin America COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 108. Latin America COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 109. Latin America COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 110. Latin America COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 111. Brazil COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 112. Brazil COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 113. Brazil COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 114. Brazil COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 115. Brazil COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 116. Argentina COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 117. Argentina COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 118. Argentina COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 119. Argentina COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 120. Argentina COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 121. Middle East & Africa COPD and asthma therapeutics market, by country, 2018 – 2030 (USD Million)

Table 122. Middle East & Africa COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 123. Middle East & Africa COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 124. Middle East & Africa COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 125. Middle East & Africa COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 126. Middle East & Africa COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 127. South Africa COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 128. South Africa COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 129. South Africa COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 130. South Africa COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 131. South Africa COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 132. Saudi Arabia COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 133. Saudi Arabia COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 134. Saudi Arabia COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 135. Saudi Arabia COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 136. Saudi Arabia COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 137. UAE COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 138. UAE COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 139. UAE COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 140. UAE COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 141. UAE COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

Table 142. Kuwait COPD and asthma therapeutics market, drug class, 2018 – 2030 (USD Million)

Table 143. Kuwait COPD and asthma therapeutics market, by device/product, 2018 – 2030 (USD Million)

Table 144. Kuwait COPD and asthma therapeutics market, by technology/software, 2018 – 2030 (USD Million)

Table 145. Kuwait COPD and asthma therapeutics market, by indication scope, 2018 – 2030 (USD Million)

Table 146. Kuwait COPD and asthma therapeutics market, by distribution channel scope, 2018 – 2030 (USD Million)

List of Figures

Fig. 1 COPD and asthma therapeutics market segmentation

Fig. 2 Market research process

Fig. 3 Data triangulation techniques

Fig. 4 Primary research pattern

Fig. 5 Market formulation & validation

Fig. 6 Market research approaches

Fig. 7 Value-chain-based sizing & forecasting

Fig. 8 QFD modelling for market share assessment

Fig. 9 Commodity flow analysis

Fig. 10 Market snapshot

Fig. 11 Market segmentation (USD Million)

Fig. 12 Competitive landscape

Fig. 13 Parent market outlook (In USD Billion)

Fig. 14 Related/ancillary market outlook (In USD Billion)

Fig. 15 COPD and asthma therapeutics market dynamics

Fig. 16 COPD and asthma therapeutics market: Porter’s five forces analysis

Fig. 17 COPD and asthma therapeutics market: PESTLE analysis

Fig. 18 COPD and asthma therapeutics market: Drug class segment dashboard

Fig. 19 COPD and asthma therapeutics market: Drug class market share analysis, 2024 & 2030

Fig. 20 Bronchodilators market, 2018 – 2030 (USD Million)

Fig. 21 Corticosteroids market, 2018 – 2030 (USD Million)

Fig. 22 Leukotriene Modifiers market, 2018 – 2030 (USD Million)

Fig. 23 Anti-IgE and Anti-IL Monoclonal Antibodies market, 2018 – 2030 (USD Million)

Fig. 24 Combination Therapy market, 2018 – 2030 (USD Million)

Fig. 25 Others market, 2018 – 2030 (USD Million)

Fig. 26 COPD and asthma therapeutics market: Device/Product segment dashboard

Fig. 27 COPD and asthma therapeutics market: Device/Product market share analysis, 2024 & 2030

Fig. 28 Inhalers market, 2018 – 2030 (USD Million)

Fig. 29 Nebulizers market, 2018 – 2030 (USD Million)

Fig. 30 Oxygen Therapy Devices market, 2018 – 2030 (USD Million)

Fig. 31 COPD and asthma therapeutics market: Technology/Software segment dashboard

Fig. 32 COPD and asthma therapeutics market: Technology/Software market share analysis, 2024 & 2030

Fig. 33 Smart Inhalers with Bluetooth Connectivity market, 2018 – 2030 (USD Million)

Fig. 34 AI-based Respiratory Monitoring Platforms market, 2018 – 2030 (USD Million)

Fig. 35 Mobile Apps for Symptom Tracking market, 2018 – 2030 (USD Million)

Fig. 36 Digital Adherence and Reminder Systems market, 2018 – 2030 (USD Million)

Fig. 37 Telepulmonology Solutions and Reminder Systems market, 2018 – 2030 (USD Million)

Fig. 38 COPD and asthma therapeutics market: Indication market share analysis, 2024 & 2030

Fig. 39 Asthma market, 2018 – 2030 (USD Million)

Fig. 40 COPD market, 2018 – 2030 (USD Million

Fig. 41 COPD and asthma therapeutics market revenue, by region

Fig. 42 Regional marketplace: Key takeaways

Fig. 43 North America COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 44 Key country dynamics

Fig. 45 US COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 46 Key country dynamics

Fig. 47 Canada COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 48 Key country dynamics

Fig. 49 Mexico COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 50 Europe COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 51 Key country dynamics

Fig. 52 UK COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 53 Key country dynamics

Fig. 54 Germany COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 55 Key country dynamics

Fig. 56 France COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 57 Key country dynamics

Fig. 58 Italy COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 59 Key country dynamics

Fig. 60 Spain COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 61 Key country dynamics

Fig. 62 Norway COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 63 Key country dynamics

Fig. 64 Sweden COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 65 Key country dynamics

Fig. 66 Denmark COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 67 Asia Pacific COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 68 Key country dynamics

Fig. 69 Japan COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 70 Key country dynamics

Fig. 71 China COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 72 Key country dynamics

Fig. 73 India COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 74 Key country dynamics

Fig. 75 Australia COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 76 Key country dynamics

Fig. 77 South Korea COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 78 Key country dynamics

Fig. 79 Thailand COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 80 Latin America COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 81 Key country dynamics

Fig. 82 Brazil COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 83 Key country dynamics

Fig. 84 Argentina COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 85 MEA COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 86 Key country dynamics

Fig. 87 South Africa COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 88 Key country dynamics

Fig. 89 Saudi Arabia COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 90 Key country dynamics

Fig. 91 UAE COPD and asthma therapeutics market, 2018 – 2030 (USD Million)

Fig. 92 Key country dynamics

Fig. 93 Kuwait healthcare information system market, 2018 – 2030 (USD Million)

Fig. 94 Company categorization

Fig. 95 Company market position analysis

Fig. 96 Strategic framework

Grand View Researchについて

Grand View Research（グランドビューリサーチ） はインドと米国を拠点とする市場調査およびコンサルティング会社です。世界中主要 25ヵ国・ 46 業界に関する豊富なデータベースを活用した市場情報は世界の企業団体に活用・引用されています。日本からのレポートのご注文・ご購入相談はお気軽にお問い合わせください。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ 1

ライセンスタイプ 2

ライセンスタイプ 3

ライセンスタイプ 4

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス（インディビジュアルライセンス）
    • 1名のみレポートファイル（印刷不可）をご利用いただけます。
  • チームライセンス
    • 同一企業（関連会社除く）内5名まで共有可能です。印刷可能な電子ファイルをご提供いたします。
  • コーポレートライセンス
    • 同一企業および関連会社内で人数無制限で共有可能です。印刷可能な電子ファイルをご提供いたします。
    • 「関連会社」の範囲についてはお気軽にお問い合わせください。
• 納品形態
  • オンラインダウンロード
• 納期
  • ご注文後1～7営業日　※レポートにより異なります。

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

最新出版レポート

• ARクラウド市場規模、成長と動向分析レポート 2025-2033年
• ノーコードAIプラットフォーム市場規模、成長と動向分析レポート 2025-2033年
• 量子コンピューティングにおけるAI最適化市場規模、成長と動向分析レポート 2025-2033年
• ワイヤレス状態監視システム市場規模、成長と動向分析レポート 2025-2033年
• ゲームストリーミング市場規模、成長と動向分析レポート 2025-2033年

出版レポート一覧